The Effects of Tricepatide on Weight Loss in Patients With Type Two Diabetes

The results of CIRM-out2, a phase three trial, up tricepatide for obesity in patients with type two diabetes, was presented at the conference. The impact was significant in terms of both the weight loss, 15% weight loss, which is quite significant, as well as A1C. And then there was another agent, ratatide. That really is an exciting agent. It's sometimes called Triple G. glucagon-like receptor agonist, GLP-1 receptor agonist and GIP agonist.